活体与 deceased 供体角膜缘干细胞移植的当前实践、技术演进与免疫挑战
本文综述同种异体角膜缘干细胞移植恢复眼表的相关内容,涵盖活体相关与 deceased 供体移植的当前实践、技术演进及免疫挑战。文章回顾角膜缘干细胞缺乏的诊断与分期指南,探讨供受体选择标准与全身免疫抑制方案,并强调三药免疫抑制方案与患者依从性对长期结局的重要性。
要点
- 活体相关结膜角膜缘同种异体移植因结局改善而较 deceased 供体角膜缘移植更受依赖。
- 三药全身免疫抑制方案与患者依从性是确保同种异体角膜缘干细胞移植长期良好结局的关键。
- 排斥反应是同种异体角膜缘干细胞移植的主要免疫挑战,静脉注射免疫球蛋白可能具有新作用。
核心结论
- 同种异体角膜缘干细胞移植是恢复眼表的重要方法,其成功依赖于合理的供受体选择、系统的免疫抑制方案及患者依从性。
研究设计与样本
- 本文为综述,聚焦同种异体来源的角膜缘干细胞移植,涵盖活体相关与 deceased 供体两种来源。
主要发现
- 活体相关结膜角膜缘同种异体移植因结局改善而较 deceased 供体角膜缘移植更受依赖。
- 老年人群中全身免疫抑制呈减少趋势,而因晚期急性排斥可能,免疫抑制疗程有所延长。
- 排斥反应是同种异体角膜缘干细胞移植的主要免疫挑战,推荐治疗中包括静脉注射免疫球蛋白的新作用。
关键数值与推荐
- 综述回顾了角膜缘干细胞缺乏的诊断与分期指南。
- 综述探讨了辛辛那提方案中的供受体选择标准与全身免疫抑制方案。
- 综述强调了panel reactive antibody、HLA分型、ABO分型及供体特异性抗体的应用。
- 综述强调了三药全身免疫抑制方案与患者依从性对确保长期良好结局的重要性。
临床怎么用
- 临床可参考辛辛那提方案进行供受体选择并制定全身免疫抑制方案。
- 应重视三药全身免疫抑制方案与患者依从性以保障长期结局。
- 对老年患者可考虑减少全身免疫抑制,但因晚期急性排斥风险需延长免疫抑制疗程。
- 排斥反应治疗中可考虑静脉注射免疫球蛋白的新作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This review focuses on allogeneic sources for restoring the ocular surface using limbal stem cell transplantation. We outline the current practices, evolving techniques, and immunologic challenges in living-related and deceased donor limbal stem cell transplantation. The diagnosis and staging guidelines for limbal stem cell deficiency are reviewed. We also explore the currently available treatment approaches, including the Cincinnati protocol for donor/recipient selection criteria and systemic immunosuppression (SI) regimen. Utilization of panel reactive antibody, HLA typing, ABO typing, and donor specific antibodies are highlighted. The traditional techniques as well as more novel variations are described. The importance of 3-agent SI protocols and patient adherence are emphasized to ensure excellent long-term outcomes. The primary immunologic challenge of allogeneic limbal stem cell transplantation, rejection, is also discussed in detail with recommended treatments, including a newer role for intravenous immunoglobulin. Other evolving practices have included a greater reliance on living-related conjunctival limbal allograft over deceased donor keratolimbal allograft due to improved outcomes, decreasing SI in older populations, and lengthening SI regimens due to the possibility of late acute rejection. Finally, we discuss the future of restoring the ocular surface via cell-based therapies, which may have the potential to decrease rejection.
引用
- Cheung AY, Auteri NJ, Holland EJ, et al. Current Practices, Evolving Techniques, and Immunologic Challenges in Living and Deceased Donor Limbal Stem Cell Transplantation. Am J Ophthalmol. 2026. PMID: 42285470. doi:10.1016/j.ajo.2026.06.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。